{"title":"Medical service utilization patterns among adults with insomnia: A retrospective cohort study","authors":"Min Kyung Hyun, Jang Won Lee","doi":"10.1016/j.eujim.2023.102325","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with insomnia can use Korean medicine (KM) alongside conventional medicine (CM) as treatment options within the Korean healthcare system, but the treatment patterns for insomnia remain unclear. This study evaluated the incidence of newly diagnosed insomnia and medical service utilization, including untreated, CM, KM, and concurrent use of CM and KM, and the determinants of treatment after the insomnia diagnosis.</p></div><div><h3>Methods</h3><p>This retrospective cohort study analyzed adult Korean patients newly diagnosed with insomnia between 2016 and 2018 using National Health Insurance Service data. The cohort who met the eligibility criteria for insomnia was followed up until 2019 to identify their medical service utilization and the determinants. The medical service utilization was defined based on outpatient visits or hospitalization records with insomnia as the primary diagnosis. Descriptive statistics and logistic regression analysis were used to identify the medical service utilization and its determinants.</p></div><div><h3>Results</h3><p>Among the 336,578 patients newly diagnosed with insomnia in 2016–2018, only 155,538 (46.21 %) received more than two insomnia treatments during the follow-up period. Of these, 104,751 (67.35 %), 41,762 (26.85 %), and 9,025 (5.80 %) patients received CM monotherapy, KM alone, and both CM and KM, respectively. The statistically significant factors for receiving insomnia treatment after diagnosis were female, age ≥30 years, Seoul capital area residents, lowest income quintile, National Health Insurance Service (NHIS) enrollment types excluding the employee type, and longer elapsed time after diagnosis. The factors for receiving KM alone rather than CM alone were female, aged 40–79 years, residents of the Seoul capital area and metropolitan city, higher income, employee type among the NHIS enrollment types, and a more recent diagnosis. The common factor for concurrent use rather than CM alone was aged 40–79 years, and concurrent use rather than KM alone was being male.</p></div><div><h3>Conclusions</h3><p>More than half of the patients with insomnia received treatment only once. The utilization of CM or KM alone was higher than that of their combined use. Healthcare professionals can utilize these findings to manage patients with insomnia effectively.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876382023001014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Patients with insomnia can use Korean medicine (KM) alongside conventional medicine (CM) as treatment options within the Korean healthcare system, but the treatment patterns for insomnia remain unclear. This study evaluated the incidence of newly diagnosed insomnia and medical service utilization, including untreated, CM, KM, and concurrent use of CM and KM, and the determinants of treatment after the insomnia diagnosis.
Methods
This retrospective cohort study analyzed adult Korean patients newly diagnosed with insomnia between 2016 and 2018 using National Health Insurance Service data. The cohort who met the eligibility criteria for insomnia was followed up until 2019 to identify their medical service utilization and the determinants. The medical service utilization was defined based on outpatient visits or hospitalization records with insomnia as the primary diagnosis. Descriptive statistics and logistic regression analysis were used to identify the medical service utilization and its determinants.
Results
Among the 336,578 patients newly diagnosed with insomnia in 2016–2018, only 155,538 (46.21 %) received more than two insomnia treatments during the follow-up period. Of these, 104,751 (67.35 %), 41,762 (26.85 %), and 9,025 (5.80 %) patients received CM monotherapy, KM alone, and both CM and KM, respectively. The statistically significant factors for receiving insomnia treatment after diagnosis were female, age ≥30 years, Seoul capital area residents, lowest income quintile, National Health Insurance Service (NHIS) enrollment types excluding the employee type, and longer elapsed time after diagnosis. The factors for receiving KM alone rather than CM alone were female, aged 40–79 years, residents of the Seoul capital area and metropolitan city, higher income, employee type among the NHIS enrollment types, and a more recent diagnosis. The common factor for concurrent use rather than CM alone was aged 40–79 years, and concurrent use rather than KM alone was being male.
Conclusions
More than half of the patients with insomnia received treatment only once. The utilization of CM or KM alone was higher than that of their combined use. Healthcare professionals can utilize these findings to manage patients with insomnia effectively.
期刊介绍:
The European Journal of Integrative Medicine (EuJIM) considers manuscripts from a wide range of complementary and integrative health care disciplines, with a particular focus on whole systems approaches, public health, self management and traditional medical systems. The journal strives to connect conventional medicine and evidence based complementary medicine. We encourage submissions reporting research with relevance for integrative clinical practice and interprofessional education.
EuJIM aims to be of interest to both conventional and integrative audiences, including healthcare practitioners, researchers, health care organisations, educationalists, and all those who seek objective and critical information on integrative medicine. To achieve this aim EuJIM provides an innovative international and interdisciplinary platform linking researchers and clinicians.
The journal focuses primarily on original research articles including systematic reviews, randomized controlled trials, other clinical studies, qualitative, observational and epidemiological studies. In addition we welcome short reviews, opinion articles and contributions relating to health services and policy, health economics and psychology.